WHO
https://www.dw.com/en/coronavirus-who-approves-sinovac-covid-vaccine-for-emergency-use/a-57750495
Approved Sinovac Biotech (CoronaVac) for emergency use
Supplying Cambodia
Inactivated
Grown in cell cultures, monkey kidney cells
Beta-propiolactone
Replication deficient
Proteins remain intact
Two dose
Now part of COVAX, but no deal yet
Capacity, 2 billion doses per year
Phase 3 data, efficacy, 51 – 91% in blocking infections
Turkey, efficacy, 91.25%
Brazil, 51%
Brazil, 83.7% in preventing medical treatment
Brazil, all deaths
Indonesia, HCWs, n = 120,000, 94% effective at preventing symptomatic illness
Sinopharm (inactivated) already approved in April
Others WHO approved
BioNTech-Pfizer, Moderna, AstraZeneca, Johnson & Johnson.
Secretary of State Antony Blinken
https://www.washingtonpost.com/national-security/blinken-coronavirus-latin-america/2021/06/01/b5ed2e10-c32c-11eb-8c18-fd53a628b992_story.html
Global distribution soon
Latin America
China, 165 million doses to Latin America and Caribbean
Sometime in the next week to two weeks we will be announcing the process by which we will distribute those vaccines
President Biden, 80 million global doses by end of June
China
https://www.washingtonpost.com/nation/2021/06/02/coronavirus-covid-live-updates-us/
May 31, 22.3 million doses given
Doses so far, 660 million
Beijing’s vaccination program got off to a slow start but has rapidly picked up pace:
China now six times faster than US peak in April
Strict border controls still in place
North Korea
https://www.reuters.com/article/health-coronavirus-northkorea/update-1-skorea-says-vaccine-shipment-to-nkorea-from-covax-delayed-again-idUSL2N2NK01H
South Korea COVAX delivery not made yet
2 million doses of AstraZeneca
Global Alliance for Vaccines and Immunization (GAVI)
Future Proof report (Centre for Long-Term Resilience)
https://drive.google.com/file/d/1LHn3nzxF2p68SfhwiPLCb5FMaMLq1dk6/view
Extreme risks
Global catastrophic risks
Existential risks
Specific risks
Biosecurity
Artificial intelligence
Climate change
Nuclear security
Biosecurity
DNA synthesis machines
Gene editing
Gain of function
Thrombocytopenia in mice reported in 2006
Blood, (2006)
https://ashpublications.org/blood/article/109/7/2832/125650/Adenovirus-induced-thrombocytopenia-the-role-of
Thrombocytopenia has been consistently reported following the administration of adenoviral gene transfer vectors.
All mice received virus through a single tail vein injection
Source